To Register for the 16th International Symposium on Translational Research in Oncology please click here
For printable version of programme please click here: 18.09.23 Programme – 16th International Symposium on Translational Research in Oncology
To register for the AICRI – Vision and Showcase event click here
16th International Symposium on Translational Research in Oncology
PROGRAMME
Wednesday, 27th September 2023, Lansdowne Suite
09.00 – 12.30 AICRI Showcase To register for the AICRI showcase click here
Registration for the Symposium from 12:30 CPD:3 external credits
13:30 – 13.45 Welcome and Introduction – Prof John Crown, St. Vincent’s Hospital Group, Dublin
TARGETED THERAPIES IN CANCER I: Session Chair – Prof. Sara Hurvitz, Fred Hutchinson Cancer Center
13:45 – 14:15 HER2 as a therapeutic target in HER2-normal breast cancer
Prof. Sara Hurvitz, Senior Vice President, Clinical Research Division, Fred Hutchinson Cancer Center, Head, Division of Hematology/Oncology, University of Washington
14:15 – 14:45 Targeting Estrogen Receptor in breast cancer: old target, new drugs
Dr. Aditya Bardia, Director, Breast Cancer Research, Medical Oncology, Massachusetts General Hospital Cancer Center, Associate Professor, Harvard Medical School, Boston
14:45 – 15:15 HER2+ GP2 vaccine and the FLAMINGO Phase III trial
Mr. Snehal Patel, CEO, Greenwich Lifesciences
15:15 – 15:30 Coffee break
TARGETED THERAPIES IN CANCER II: Session Chair – Prof. Sara Hurvitz, Fred Hutchinson Cancer Center
15:30 – 16:15 Patient-derived models of breast cancer for drug discovery and precision medicine
Dr. Alana Welm, Huntsman Cancer Institute, University of Utah, Salt Lake City
16:15 – 16:45 TPD squared – Dual-Precision Targeted Protein Degradation For Oncology Therapeutics Discovery and Development
Dr. James Palacino, VP/Head of Biology, Orum Therapeutics
KEYNOTE PRESENTATION
16:45 – 17:15 Topic: CDK inhibitors and the NATALEE trial
Dr. Dennis J. Slamon, 2019 Lasker Award Winner, Director of Clinical/Translational Research, Director of the Revlon/UCLA Women’s Cancer Research Program at JCCC. Professor of Medicine, Chief, Division of Hematology/Oncology UCLA.
____________________________________________________________
Thursday, 28th September 2023, Lansdowne Suite, Herbert Park Hotel
Registration from 08:30 CPD: 6 external credits
TUMOUR MICRO-ENVIRONMENT I: Session Chair – Prof. Bob Kerbel, University of Toronto
09:00 – 09:30 Modulation of the tumor associated fibronectin ECM to enhance efficacy of immune checkpoint blockade
Prof Robert Kerbel & Dr. Kabir Khan, Sunnybrook Research Institute, University of Toronto
09:30 – 10:00 Overcoming endothelial cell anergy for improvement of immunotherapy against cancer
Prof Arjan Griffioen, Head of the Angiogenesis Laboratory, Amsterdam UMC
10:00 – 10:30 Orally available RGD-mimetic and enhancement of immunotherapy efficacy
Prof Kairbaan Hodivala Dilke, Professor of Tumour Microenvironment, Queen Mary University of London, and Deputy Director of Barts Cancer Institute.
10:30 – 10:45 Coffee break
TUMOUR MICRO-ENVIRONMENT II: Session Chair – Prof. Bob Kerbel, University of Toronto
10:45 – 11:15 Brain metastasis in the era of immunotherapy: implications for sequential immunotherapy-based combination therapy
Prof Yuval Shaked, Dept of Cell Biology and Cancer Science, Rappaport Faculty of Medicine, Technion, Israel. Director of the Rappaport-Technion Integrated Cancer Center
11.15 – 11:45 Control of malignant properties by functionally and spatially distinct cancer-associated fibroblasts
Professor Kristian Pietras, Division of Translational Cancer Research, Lund University Cancer Centre
11:45 – 12:15 Extracellular Vesicles in the Tumour Microenvironment
Prof Lorraine O’Driscoll, School of Pharmacy & Pharmaceutical Sciences, Panoz Institute & Trinity Biomedical Sciences Institute & Research Director, Trinity St. James’s Cancer Institute, Trinity College Dublin
KEYNOTE PRESENTATION
12:15 – 13:00 Normalizing the tumor microenvironment to improve immunotherapy of brain tumors: Emerging insights and strategies
Prof. Rakesh Jain, National Medal of Science Awardee 2013, Andrew Werk Cook Professor of Tumor Biology, Massachusetts General Hospital, Harvard Medical School & Director E.L. Steele Laboratories for Tumor Biology, Massachusetts General Hospital.
13:00 – 14:00 Lunch
Targeting Difficult to Drug Genes for Cancer Therapy: Session Chair – Prof Michael J. Duffy, St. Vincent’s University Hospital/University College Dublin
14:00 – 14:30 Targeting MYC: A Dual Effect on Both Cancer Cells and Tumor Microenvironment
Prof Michael J. Duffy, Clinical Research Centre, St. Vincent’s University Hospital, Dublin.
14:30 – 15:00 Biomarker driven development of Brigimadlin, a MDM2-p53 antagonist restoring p53 activity
Dr. Michael Teufel, Exec Dir Translational Medicine & Clinical Pharmacology, Boehringer Ingelheim
15:00 – 15:30 Combination strategies to potentiate the impact of KRAS inhibitors
Dr. Miriam Molina-Arcas, Oncogene Biology Laboratory, The Francis Crick Institute
15:30 – 15:45 Coffee break
Novel Targeted therapies: Session Chair – Prof Denis Collins, Dublin City University
15:45 – 16.15 Development of a novel therapeutic mAb and ADC for CLDN18.2
Dr. Neil O’Brien, Adj Associate Professor, Dept of Medicine, Division of Hematology/Oncology, UCLA
16:15 – 16:45 Selective Therapies for Metastatic Tumor Cells
Prof Bruce Zetter, Charles Nowiszewski Professor of Cancer Biology, Harvard
16:45 – 17:15 Evolving insights into biomarkers and treatment of hepatocellular carcinoma
Prof. Richard Finn, Division of Hematology/Oncology, David Geffen School of Medicine, UCLA.
17:15 – 17:45 Development and characterisation of an anti-Claudin-6 (CLDN6) ADC for the treatment of CLDN6 positive cancer
Dr. Martina McDermott, Adj Assoc Prof, Dept of Medicine, Division of Hematology/Oncology, UCLA ______________________________________________________________
Friday 29th September 2023, Lansdowne Suite, Herbert Park Hotel
Registration from 8:30 CPD: 4 external credits
CANCER IMMUNOTHERAPY I – exploiting immune cells: Session Chair – Prof. Mario Sznol, Yale
09:00 – 09:30 DGKα/ζ inhibition lowers the TCR affinity threshold and potentiates anti-tumor immunity
Dr. Michael Dougan, Massachusetts General Hospital, Harvard Medical School
09:30 – 10:00 Novel Biomarker Discovery for NX-1607: Clinical Insights into a First-in-Class Oral CBL-B Inhibitor for Advanced Malignancies
Dr. Sarah Whelan, Associate Director, Translational Medicine, Nurix Therapeutics
10:00 – 10:30 ACTengine® IMA203 TCR-T: Unleashing the Potential of Targeting PRAME in Solid Tumors
Prof. Dr. med Oliver Ebert, Senior Director, Head of Clinical Development, Immatics
10:30 – 11:00 Cancer cell metabolomics and immunotherapy resistance
Prof. Ken O’ Bryne, Professor of Medical Oncology, Queensland University of Technology
11:00 – 11:15 Coffee break
CANCER IMMUNOTHERAPY II: Session Chair – Prof. Mario Sznol, Yale
11:15-11:45 Cis-targeting of IL-2 and IL-21 cytokines to CD8+ T cells to improve immunotherapies for cancer
Dr. Ivana Djuretic, Chief Scientific Officer, Asher Biotherapeutics
11:45 – 12:15 Development of XTX301, a bioengineered masked, tumor-activated IL-12: unleashing the potent cytokine in the tumor microenvironment
Dr. Katarina Luptakova, MD, Senior Vice President, Medical, Xilio Therapeutics
12:15 – 12:45 New Strategies in Immuno-Oncology: Tumor-directed Oncolytic Immunotherapy (TOI)
Dr. Giuseppe Gullo, Executive Medical Director, Clinical Development, Replimune
12:45 – 13:00 Q & A
13:00 – 14:00 Lunch
Novel targeted drugs & biomarkers: Session Chair – Prof William Gallagher, University College Dublin
14:00 – 14:30 Cancer as a combinatorial challenge
Dr. Lajos Pusztai, Professor of Medicine, Yale University and Director of Breast Cancer Translational Research and Co-Director of the Cancer Center Genomics, Genetics, and Epigenetics Program
14:30 – 15:00 Targeting mediator kinases in prostate and breast cancers
Prof Igor Roninson, CSO, Senex Biotechnology & Prof Eugenia Broude, University of South Carolina
15:00 – 15:30 The role of MRD detection and quantitation in solid tumors
Dr Minetta Liu, Chief Medical Officer, Natera
15:30 – 15:45 Coffee break
Novel targeted drugs & biomarkers II: Session Chair – Prof John Crown, St Vincent’s Hospital
15:45 – 16:15 Understanding TIL therapy for metastatic melanoma
Prof John Haanen, Medical Oncology Dept. Netherlands Cancer Institute
16:15 – 16:45 A Phase 1/2 Study of a First-in-Human Immune-Stimulating Antibody Conjugate (ISAC) BDC-1001 in Patients with Advanced HER2-Expressing Solid Tumors (NCT04278144)
Dr. Mark Pegram, Susy Yuan-Huey Hung Prof Med Oncology, Stanford University School of Medicine
16:45 – 17:15 Topic: Fianlimab (anti-LAG-3) and cemiplimab (anti-PD-1) in advanced melanoma
Prof. John Crown, Consultant Medical Oncologist, St Vincent’s Hospital, Dublin; Professor of Oncology, University College Dublin; Thomas Baldwin Chair of Translational Oncology, Dublin City University
Meeting Ends